NR3C1 and breast carcinoma: In addition to the desired systemic effects of glucocorticoids, it is important to recall that GR is expressed in 50–70% of breast cancers, is highly correlated with ER and FOXA1 expression [145], and is prognostic of favorable patient outcomes when examining all breast cancers as a group [146].